ANAmira Naimi

Amira Naimi

*This is an algorithmically generated author record based on publicly available information.

Amira Naimi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of a Cell-Permeable Gi-Signaling Inhibitor

    by Amira Naimi, Tim Berger, Philipp Dahlhaus, Marcel Rossol, Jonas Muehle, Wieland Steinchen, Gert Bange, Uwe Linne, Paolo Stincone, Xavier Deupi, et al.

    Heterotrimeric G proteins regulate diverse physiological processes, yet selective small molecule modulators for the Gα i subfamily remain scarce. Here, we employed native metabolomics to screen a fungal culture collection for G protein binders, which led to the discovery of N-hydroxyapiosporamide (NHAP), a fungal specialized metabolite that functionally inhibits Gi-signaling. NHAP selectively binds Gα i1 and diminishes Gα i1 -mediated GTP turnover in biochemical assays. In primary ventricular cardiomyocytes, NHAP largely reversed acetylcholine-induced negative inotropy, demonstrating functional Gi-signaling blockade in a physiological context without acute cytotoxicity. This work establishes NHAP as a first-in-class Gi-selective inhibitor, providing a cell-permeable chemical scaffold for the optimization of next-generation agents to control Gi-signaling in cell-based systems and, ultimately, to target Gα i1 -driven pathologies.

  • Open Access

    Native Metabolomics Unveils Suomilide Analogs with Potent Trypsin Inhibitory Activity

    by Amira Naimi, Christoph Ulbricht, Tung Lam Trinh, Stefan Kehraus, Teresa Marina Dreckmann, Uwe Linne, Kornelia Hardes, Raphael Reher, Martin Baunach

    Cyanobacteria are well-known for their ability to produce a diverse array of serine protease inhibitors and thus are a promising source of pharmaceutical lead structures. Here, native metabolomics was employed with trypsin to rapidly screen whole cyanobacterial metabolomes and uncover new potent inhibitors. In combination with subsequent correlative LC-HR-MS/MS-based analysis, this led to the fast discovery of the well-characterized natural product family of suomilides from Nostoc sp. KVJ20 as highly potent trypsin inhibitors. Notably, two of the six putative binders were recognized as potential unknown analogs and thus were chosen for isolation and structural elucidation by means of 1D/2D NMR spectroscopy, Marfey's analysis, and bioinformatic investigations. This resulted in the identification of new suomilides G and H (1/2), which were isolated together with the known congeners suomilide B (3) and D (4). We also demonstrated that all four isolated suomilides inhibit trypsin at low nanomolar to high picomolar concentrations in a competitive bioassay, confirming the exceptional potency of this growing compound family as protease inhibitors.